Newsfeeds - Spark Newswire

3 minute read

FDA
News

Lumos Pharma Earlier Announced Clinical Updates; Says OraGrowtH210 Trial In PGHD Primary Outcome 6-Month Data Now Anticipated In H2 2023

Today, 11:25 PM

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announces an update on clinical activities. Phase 2 OraGrowtH210 Trial Primary 6-Month Data

LUMO

5 minute read

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study

By Shanthi Rexaline

Today, 11:25 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)

ABCL

26 minute read

Uncategorized

Earnings Scheduled For May 5, 2021

By Benzinga Insights

Today, 11:25 PM

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.

AAWW

8 minute read

Uncategorized

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge

By Shanthi Rexaline

Today, 11:25 PM

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.

ABUS

Latest news

Lumos Pharma Earlier Announced Clinical Updates; Says OraGrowtH210 Trial In PGHD Primary Outcome 6-Month Data Now Anticipated In H2 2023

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study

Earnings Scheduled For May 5, 2021

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge